Search results

1 – 1 of 1
To view the access options for this content please click here
Article
Publication date: 8 April 2020

Raghavendar Baburaj, Huw Morgan Dunstall, Catherine Bright and Charlotte Lawthom

Epilepsy is a chronic illness affecting around 50 million people worldwide. Levetiracetam is an effective novel antiepileptic drug but can cause behavioural adverse…

Abstract

Purpose

Epilepsy is a chronic illness affecting around 50 million people worldwide. Levetiracetam is an effective novel antiepileptic drug but can cause behavioural adverse events. A total of 10-15 per cent people with intellectual disability (ID) already present with Behaviour that Challenges (BtC). Brivaracetam is postulated to have a distinct pharmacological profile compared with levetiracetam which may result in fewer behavioural adverse events.

Design/methodology/approach

This paper presents two cases of people with epilepsy and ID being switched from levetiracetam to brivaracetam for reported behaviour adverse events.

Findings

The cases support that people with epilepsy and ID who are experiencing behavioural adverse events from levetiracetam can safely be switched to brivaracetam, resulting in significant reductions in BtC and potentially improved seizure control. Nevertheless, these results must be interpreted with caution, as aetiology for BtC in people with ID is often multifactorial.

Originality/value

This is one of the first papers to date, according to the best of the authors’ knowledge, to describe improved behavioural profile in people with ID and epilepsy when switching from levetiracetam to brivaracetam.

Details

Advances in Mental Health and Intellectual Disabilities, vol. 14 no. 3
Type: Research Article
ISSN: 2044-1282

Keywords

1 – 1 of 1